Chris Viehbacher once again sets out to revamp R&D at a major biopharma. The last try led to his ouster
An outspoken Chris Viehbacher spent six years trying unsuccessfully to prod Sanofi’s multibillion-dollar R&D group into a more productive phase that relied less on partners like Regeneron for their big new drugs. Then it all went up in smoke as chairman Serge Weinberg led the board in ousting him from the CEO suite, complaining about Viehbacher’s management style and persistent efforts to carve down the French staff.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.